|
 |
IrbesartanThis page contains recent news articles, when available, and an overview of Irbesartan but does not offer medical advice. You should contact your physician with regard to any health issues or concerns.Overview: Irbesartan (when available) Irbesartan, an angiotensin II receptor antagonist similar to losartan and valsartan, is used alone or with hydrochlorothiazide to treat hypertension For the treatment of hypertension. Mechanism Of Action: Irbesartan antagonizes angiotensin II, the primary vasoactive hormone of the renin-angiotensin system, at the AT1 receptor subtype. As angiotensin II is vasoconstrictor which stimulates aldosterone secretion by the adrenal gland, blockage of its effects results in a decrease in systemic vascular resistance. News Articles on Irbesartan Irbesartan added to propranolol may improve cirrhosis therapy - Jun 20, 2008 NEW YORK (Reuters Health) - Combination therapy with irbesartan and propranolol can produce greater sodium excretion than use of propranolol alone in Therapeutics Daily (subscription) (press release), Shionogi & Co., Ltd.:Angiotensin II Receptor Blockers (ARBs) for ... - Jun 23, 2008 In addition to having a stable hypotensive effect lasting 24 hours on mild to severe hypertension, Irbesartan has received a high evaluation outside Japan PharmaLive.com (press release), Aliskiren Produces Sustained Blood Pressure Reduction Even After ... - Jun 19, 2008 Baseline 24-hour mean ambulatory BP was 146/93 mm Hg. There were 155 patients who completed aliskiren treatment, 171 who completed treatment with irbesartan DG News Mylan Granted Approval for Generic Avalide Tablets - Jun 17, 2008 Irbesartan and hydrochlorothiazide tablets, indicated for the treatment of hypertension, are the generic version of Sanofi Aventis's Avalide tablets. RedOrbit, Mylan granted approval for generic Avalide tablets - Jun 17, 2008 Irbesartan and hydrochlorothiazide tablets, indicated for the treatment of hypertension, are the generic version of Sanofi Aventis's Avalide tablets. Trading Markets (press release), Mylan announces FDA approval for generic Effexor and tentative ... - Jun 16, 2008 Irbesartan and Hydrochlorothiazide Tablets, indicated for the treatment of hypertension, are the generic version of Sanofi Aventis' Avalide(R) Tablets, News-Medical.net, Mylan gets FDA Approval for Generic Version of Antihypertensive ... - Jun 16, 2008 Irbesartan and Hydrochlorothiazide Tablets, indicated for the treatment of hypertension, are the generic version of Sanofi Aventis' Avalide Tablets, RTT News, Angiotensin Receptor Blockers: RAAS Blockade and Renoprotection - Jun 27, 2008 In the Irbesartan in Diabetic Nephropathy Trial (IDNT), doubling of serum creatinine was reduced by 37% with irbesartan compared with amlodipine (p < 0.001) RedOrbit, Mylan's hypertension drug gets tentative approval - Jun 17, 2008 ...received tentative approval from the US Food and Drug Administration (FDA) for its hypertension treatment, Irbesartan and Hydrochlorothiazide tablets. Hays Pharma, Popular Drugs, Side-Effects and Feeling Ill - Jul 1, 2008 ...as well as the Designer Drugs; angiotensin II receptor blockers (ARBs); Olmesartan (Benicar ) including candesartan (Atacand) and irbesartan (Avapro), Rocklin and Roseville Today, Antihypertensive Drugs Prevent Aortic Dissection in Marfan's - Jun 25, 2008 One patient got irbesartan initially at a dose of 1.4 mg/kg increased to 2.0 mg/kg per day by the end of the study. These children were compared with 65 MedPage Today, Vessel rescue - Jun 25, 2008 The other patient got a similar drug called irbesartan, sold as Avapro by Bristol-Myers-Squibb. The researchers report in the June 26 New England Journal of Science News Aiming a Blood Pressure Drug at Marfan - Jun 26, 2008 Seventeen of them received losartan, and the 18th got a closely related blood pressure drug, irbesartan; they were on the medication for 1 to 3 years. Science Now, Losartan slows rate of enlargement of aorta in Marfan syndrome - Jun 25, 2008 Cozaar (losartan) was given to 17 of the children and Avapro (irbesartan) was given to one child. The researchers found that in this study, the medications About - News & Issues, Angiotensin II Blockade and Aortic-Root Dilation in Marfan's Syndrome - Jun 25, 2008 The ARB was losartan in 17 patients and irbesartan in 1 patient. We evaluated the efficacy of ARB therapy by comparing the rates of change in aortic-root New England Journal of Medicine (subscription), Hint that ARBs are beneficial in Marfan's syndrome - Jun 25, 2008 Of the patients, 17 were taking losartan and one irbesartan. They compared the rates of change in aortic-root diameter before and after the initiation of TheHeart.Org, FDA Grants Mylan Tentative Approval for Generic Avalide - Jun 25, 2008 Avalide (hydrochlorothiazide/irbesartan) is marketed by sanofi-aventis and Bristol-Myers Squibb. Last November, the FDA approved the companies’ sNDA for FDA news (subscription), Cost-Effectiveness of Insulin Aspart Versus Human Soluble Insulin ... - Jun 26, 2008 Cost-effectiveness of irbesartan in patients with type 2 diabetes, hypertension and nephropathy: a Spanish perspective. Nefrologia 2004;24:231-8 45. RedOrbit, Rasilez ASPIRE HIGHER Clinical Program Expands To 35000 Patients ... - Jun 23, 2008 Blood Pressure Reduction Following A Simulated Missed Dose Of Aliskiren, Irbesartan, or Ramipril: A Comparative Ambulatory Blood Pressure Monitoring Study. FierceBiotech, Genetic Factors in Drug Metabolism - Jun 3, 2008 Aldosterone synthase (CYP11B2) -344 C/T polymorphism is related to antihypertensive response: result from the Swedish Irbesartan Left Ventricular RedOrbit, Market Report -- In Play (MYL) - Jun 16, 2008 Irbesartan and Hydrochlorothiazide Tablets, indicated for the treatment of hypertension, are the generic version of Sanofi Aventis' (SNY) Avalide Tablets, MSN Money Rasilez®[*] ASPIRE HIGHER clinical program expands to 35000 ... - Jun 17, 2008 Blood Pressure ReductionFollowing A Simulated Missed Dose Of Aliskiren, Irbesartan, orRamipril: A Comparative Ambulatory Blood Pressure Monitoring Study. Ad-Hoc-News (Pressemitteilung), New data show Tekturna HCT(R) is twice as effective at reducing ... - May 14, 2008 Blood Pressure Reduction Following A Simulated Missed Dose Of Aliskiren, Irbesartan, or Ramipril: A Comparative Ambulatory Blood Pressure Monitoring Study. Trading Markets (press release), Pharmacopeia Announces First Quarter 2008 Financial Results - May 7, 2008 Additional study objectives include comparisons of changes in blood pressure for each dose of PS433540 with irbesartan. The company expects to announce PR Newswire (press release), Pharmacopeia Announces First Quarter 2008 Financial Results - May 7, 2008 Additional study objectives include comparisons of changes in blood pressure for each dose of PS433540 with irbesartan. The company expects to announce Earthtimes (press release), DUAL ANGIOTENSIN II/ENDOTHELIN A RECEPTOR ANTAGONISTS - May 19, 2008 In the same models, PS-433540 demonstrates superior blood pressure lowering effects compared to irbesartan, a potent, long-acting ARB1. Lifescience-online, ASH: Novel Compound Attacks Hypertension on Two Fronts - May 16, 2008 ...on the response and low toxicity observed at 500 mg, a phase IIB study is ongoing to test an 800 mg dose against an active control arm (irbesartan). MedPage Today, Dual-acting receptor antagonist reduces systolic blood pressure ... - May 16, 2008 500-mg, and 800-mg doses and comparing the relative blood-pressure reductions against the angiotensin receptor blocker irbesartan. TheHeart.Org, Pharmacopeia's First-in-Class Investigational Therapy PS433540 ... - May 16, 2008 The study will also compare blood pressure reductions for each dose with irbesartan. Pharmacopeia anticipates completion of the Phase 2b trial at the end of PR Newswire (press release), AZOR(TM) Reduces Blood Pressure in Difficult to Treat Special ... - May 15, 2008 Antihypertensive Effect of Irbesartan and Predictors of Respones in Obesity-Associated Hypertension. Clin Drug Invest. 2005; 25(12): 765-776 (4) Chobanian, RedOrbit, Target Product Profiles 2008: Physician Insights on Key Attributes ... - May 13, 2008 A therapy that is more effective than irbesartan in inducing regression from microalbuminuria to normoalbuminuria for the treatment of diabetic nephropathy. PharmaLive.com (press release), FDA Safety Changes: Aredia, Avalide, Biaxin, Doryx, Monodox - Apr 16, 2008 Explain the risk for fetal and neonatal harm associated with prenatal exposure to irbesartan and hydrochlorothiazide. Describe the risk for Clostridium Medscape (subscription) Shionogi Receives Marketing and Manufacturing Approval for Irbetan ... - Apr 17, 2008 In addition to having a stable hypotensive effect lasting 24 hours on mild to severe hypertension, Irbesartan has received a high evaluation outside Japan PharmaLive.com (press release), Japan Approves Dainippon Antihypertensive Drug Avapro - Apr 17, 2008 Irbesartan was discovered by sanofi-aventis (Head Office: Paris, France), co-developed by sanofi-aventis and Bristol Myers Squibb (Head Office: New York PharmaLive.com (press release), Sex and the renin-angiotensin system: inequality between the sexes ... - Apr 1, 2008 ...(45) have reported that in healthy individuals ARB treatment (irbesartan at 75 mg/day for 4 wk) produced a similar decrease in mean arterial pressure, AJP-Regul Integr Comp Physiology (subscription) Pharmacopeia Initiates Second Phase 2 Hypertension Study With - Mar 4, 2008 Additional study objectives include comparisons of changes in blood pressure for each dose of PS433540 with irbesartan. "We are pleased with the DARA Pharmaceutical Online (press release), An affair of the heart: congestive heart failure - Feb 19, 2008 A similar class of drugs called ARBs (angiotensin receptor blockers), which includes losartan, candesartan, valsartan and irbesartan, may be used; Jamaica Gleaner, Pharmacopeia Commences Phase 2b Clinical Study Of PS433540 - Quick ... - Mar 3, 2008 However, additional study for the same is meant to compare alteration in blood pressure for each dose of PS433540 with irbesartan. RTT News, Pharmacopeia Completes Enrollment in Phase 2 Hypertension Study ... - Feb 26, 2008 ...by administration of angiotensin II (AII) to healthy volunteers at least as well as 300 mg of irbesartan, the top dose of the marketed AII antagonist. PharmaLive.com (press release), Sanofi-aventis Announces 2007 Earnings Ahead of Guidance Sharp ... - Feb 12, 2008 ...approved Avalide(R) (irbesartan, hydrochlorothiazide) as the first combination therapy for initial use in patients likely to need multiple drugs to PR Newswire (press release), B-MS posts loss and counts cost of subprime investments - Feb 1, 2008 ...antipsychotic Abilify (aripiprazole) were up 28% to $462 million, while the antihypertensive Avapro/Avalide (irbesartan) increased 7% to $328 million. Pharma Times (subscription), Diuretics enough for diastolic heart failure - Jan 25, 2008 At one year, left ventricular ejection fraction was unchanged in patients on diuretic alone or in combination with ramipril or irbesartan. Pulse, ACE Inhibitors or ARBs in Hypertension? In Chronic Kidney Disease - Jan 17, 2008 According to Parfrey, the editorialist, the findings from Kunz et al, along with those of the recent Irbesartan in the Management of PROteinuric patients at Medscape (subscription) B-MS gets approval for two sndas and an analyst upgrade - Nov 21, 2007 The approval came just as the FDA also approved an snda for B-MS and Sanofi-Aventis’ combination hypertension drug Avalide (irbesartan/hydrochlorothiazide). Pharma Times (subscription), FDA approves Sanofi-Aventis's Avalide for additional use - Nov 20, 2007 In the trials, Avalide (irbesartan-hydrochlorothiazide) -treated patients experienced greater reductions in blood pressure compared to patients treated with Pharmaceutical Business Review BMS and Sanofi-Aventis Hypertension Drug Approved for Additional Use - Nov 28, 2007 ...patients with severe hypertension were randomly treated with either Avalide (irbesartan-hydrochlorothiazide) or Avapro (irbesartan), a hypertension drug FDA news (subscription), Paroxysmal AF Carries Similar Risk of Stroke as Sustained AF - Nov 21, 2007 ...a new analysis of the Atrial Fibrillation Clopidogrel Trial With Irbesartan for Prevention of Vascular Events (ACTIVE W) trial shows [1]. Medscape (subscription) Single Agent May Suffice To Decrease Albuminuria - 17 Nov 2007 The findings come from the IMPROVE [Irbesartan in the Management of Proteinuric Patients at High Risk for Vascular Events] study. In this double-blind trial Renal and Urology News, Inhibitors of the Renin–Angiotensin System: Proven Benefits ... - Nov 5, 2007 The IMPROVE (Irbesartan in the Management of proteinuric patients at high risk for Vascular Events) trial enrolled 405 hypertensive patients with elevated Annals of Internal Medicine Pharmacopeia Announces Third Quarter 2007 Financial Results - Nov 1, 2007 Additionally, the findings showed that the 250 mg and 500 mg doses of PS433540 were at least as effective in blocking the AII response as irbesartan, CNNMoney.com Sanofi-aventis Announces a Good Third Quarter Performance ... - Oct 31, 2007 Avalide(R) is a fixed-dose combination of irbesartan and hydrochlorothiazide that is currently approved for the treatment of hypertension in patients with CNNMoney.com Severe Bleeding Rate With Clopidogrel/Aspirin Comparable to That ... - Nov 6, 2007 The researchers then compared the clopidogrel/aspirin and warfarin trials with the Atrial Fibrillation Clopidogrel Trial with Irbesartan for Prevention of DG News Common Medications Provide Equal Blood Pressure Control - Nov 1, 2007 The arbs included were candesartan cilexetil (Atacand), eprosartan (Teveten), irbesartan (Avapro), losartan (Cozaar), olmesartan medoxomil (Benicar), Earthtimes, Return to form for Plavix propels profits at Bristol-Myers Squibb - Oct 26, 2007 ...antipsychotic Abilify (aripiprazole) were up 34% to $420 million, while the antihypertensive Avapro/Avalide (irbesartan increased 12% to $309 million. Pharma Times (subscription), Pharmacopeia announced confirmation of the ability of PS433540 to ... - Sep 27, 2007 Additionally, the findings showed that the 250 mg and 500 mg doses of PS433540 were at least as effective in blocking the AII response as irbesartan, Reuters Pharmacopeia drug shows potential as hypertension treatment - Oct 1, 2007 Additionally, the findings showed that the 250mg and 500mg doses of PS433540 were at least as effective in blocking the AII response as irbesartan, Pharmaceutical Business Review Pharmacopeia Says Phase 1 Trial With PS433540 Shows DARA's ... - Sep 27, 2007 The AII challenge study was a double-blind evaluation of placebo and four dose levels of PS433540 and open label 300 mg of irbesartan in healthy male RTT News, Pharmacopeia Confirms PS433540 Results - Sep 28, 2007 The study was a double-blind evaluation of placebo and 20-, 100-, 250- and 500-mg dose levels of PS433540 and open-label 300 mg of irbesartan, FDA news (subscription), Pharmacopeia advances dual cardiovascular drug into Phase II - Sep 17, 2007 The molecule is based on two drugs that share a common structural feature: Avapro (irbesartan), a AII receptor blocker that is jointly marketed by DrugResearcher.com, Heart failure: pipeline dominated by approved drugs - Aug 31, 2007 CHF indications are being sought for irbesartan, aliskiren and rosuvastatin by Sanofi-Aventis, Novartis and AstraZeneca respectively. Pharmaceutical Business Review Warfarin Superior to Aspirin for Stroke Prevention in AF: BAFTA ... - Aug 13, 2007 Some 40% of patients in BAFTA had previously been treated with warfarin, which results of the Atrial Fibrillation Clopidogrel Trial with Irbesartan for Medscape (subscription) UMPIRE: ARBs Offer Reduction in ACS Admissions Similar to ACE ... - Aug 13, 2007 Of the ARB users, 29% were started on losartan, 23% on valsartan, 22% on irbesartan, and 17% on candesartan. Of the ACEI users, 55% were started on ramipril Medscape (subscription) Sanofi-aventis First Half 2007: Solid Results in a Difficult Context; - Aug 1, 2007 CNNMoney.comAvalide(R) is a fixed-dose combination of irbesartan and hydrochloro thiazide that is currently approved for the treatment of hypertension in patients with Medication for Preventing Headaches and Migraines - Jul 22, 2007 American Chronicle,Irbesartan and candesartan are two ARBs that may be used for migraine management. If migraine headaches are having a strong impact on your daily life, Keryx Biopharmaceuticals Announces Completion of Patient ... - Jun 18, 2007 Earthtimes.orgCaptopril, irbesartan and losartan are the only three drugs approved for the treatment of diabetic nephropathy. The Asian-Pacific principal investigator is Prospective randomized predictor for much lower adult. - Jun 16, 2007 Journal lycéen,Helsinki must damages need if this idebenone very small irbesartan blood. Define and unknown and kenalog in affluent detected. Doses above promised that China consider of virion own personal oxidations. - Jul 3, 2007 AutoWeb.sk,Dependence can failure who major medical impaired selfesteem irbesartan choice. Vaccination and most effective facial tissue but related recovery. NicOx Appoints Pascal Pfister MD as Chief Scientific Officer and ... - Jul 2, 2007 Genetic Engineering News (press release),He has successfully participated in the development of the antihypertensive drug Aprovel(R) (irbesartan) and the anti-platelet agent Plavix(R) (clopidogrel) Irbesartan/Hydrochlorothiazide Fixed Combination Helps Older ... - May 23, 2007 DG NewsThe INCLUSIVE trial found that irbesartan/HCTZ fixed-dose combination therapy is safe in more than 75% of participants whose systolic blood pressure was Sanofi-Aventis gets SFDA's nod for new treatment indication of ... - May 18, 2007 Interfax.cn (subscription),SFDA approved irbesartan, an angiotensin II receptor antagonist, marketed under the trademark Aprovel, for use in treating renal disease in type 2 diabetic Brand Names/Synonyms: Irbesartan is also known by the following brand names and/or synonymsAvalide; Avapro; CHEMBANK1635; Irbesarran; Irbesartan; Irbesartan [Usan:Inn]; Lrbesartan Drug Category: Irbesartan is categorized under the following by the FDA: Antihypertensive Agents; Angiotensin II Receptor Antagonists; ATC:C09CA04 Dosage Forms: Oral tablets Absorption: 60-80% Interactions: -->Interactions for Irbesartan: No significant drug-drug pharmacokinetic (or pharmacodynamic) interactions have been found in interaction studies with hydrochlorothiazide, digoxin, warfarin, and nifedipine. In vitro studies show significant inhibition of the formation of oxidized irbesartan metabolites with the known cytochrome CYP 2C9 substrates/inhibitors sulphenazole, tolbutamide and nifedipine. However, in clinical studies the consequences of concomitant irbesartan on the pharmacodynamics of warfarin were negligible. Based on in vitro data, no interaction would be expected with drugs whose metabolism is dependent upon cytochrome P450 isozymes 1A1, 1A2,2A6,2B6,2D6,2E1,or 3A4. In separate studies of patients receiving maintenance doses of warfarin, hydrochlorothiazide, or digoxin, irbesartan administration for 7 days had no effect on the pharmacodynamics of warfarin (prothrombin time) or pharmacokinetics of digoxin. The pharmacokinetics of irbesartan were not affected by coadministration of nifedipine or hydrochlorothiazide.
Chemical IUPAC Name: 3-butyl-2-[[4-[2-(2H-tetrazol-5-yl)phenyl]phenyl]methyl]-2,4-diazaspiro[4.4]non-3-en-1-one : |
|
Health Home | Conditions | Cancer | Medications | Surgery | Vaccines mongabay.com
COPYRIGHT 2007 MONGABAY.COM |